ArticleACS medicinal chemistry letters2019
Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Targeting ABL Tyrosine Kinase in Chronic Myeloid Leukemia: Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Thiazolone Derivatives.Pharmaceutics · 2026Article
- Chromones as Nonclassical Inhibitors of Carbonic Anhydrase IX and XII Isoforms: Probing Chromone-Based Derivatives.Archiv der Pharmazie · 2026Article
- Design, synthesis, anticancer activity, bioimaging, and molecular docking of novel fluorescent isatin derivatives.Investigational new drugs · 2026Article
- Synthesis, In-Silico Molecular Docking Studies, and In-Vitro Antimicrobial Evaluation of Isatin Scaffolds bearing 1, 2, 3-Triazoles using Click Chemistry.Indian journal of microbiology · 2025Article
- Design, Synthesis, and Antitumor Potential of New Thiazolecontained 5-Fluoro-2-Oxindole Derivatives as Sunitinib Analogues.Current medicinal chemistry · 2025Article
- A Review on Indole-triazole Molecular Hybrids as a Leading Edge in Drug Discovery: Current Landscape and Future Perspectives.Current topics in medicinal chemistry · 2024Review
- Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia.International journal of molecular sciences · 2023Article
- Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Synthesis, Characterization, and Antibacterial Activity of New Isatin Derivatives.Pharmaceutical chemistry journal · 2023Article
- Effect of sunitinib derivatives on glioblastoma single-cell migration and 3D cell cultures.American journal of cancer research · 2023Article
- Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Effect of 1,2,4-Triazole-3-thiol Derivatives Bearing Hydrazone Moiety on Cancer Cell Migration and Growth of Melanoma, Breast, and Pancreatic Cancer Spheroids.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- NovelInternational journal of molecular sciences · 2021Article
- Antioxidant and Anticancer Activity of Novel Derivatives of 3-[(4-Methoxyphenyl)amino]propane-hydrazide.Molecules (Basel, Switzerland) · 2020Article
- Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases.Journal of enzyme inhibition and medicinal chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of isatin-dihydropyrazole hybrids have been synthesized in order to assess their potential as anticancer agents. In particular, 12 compounds were evaluated for their antiproliferative activity toward A549, IGR39, U87, MDA-MB-231, MCF-7, BT474, BxPC-3, SKOV-3, and H1299 cell lines, and human foreskin fibroblasts. Four compounds exhibited interesting antiproliferative activity and were further examined to determine their EC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.